The recently launched BRCA Care program may increase test access in six countries, though it cannot ensure access to downstream interventions based on results.
The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.
Data from ESMO positioned the competing checkpoint inhibitors as potential new standards of care in the first-line setting, but biomarker questions remain.
Trial data, however, raised doubt about Lynparza's benefit in metastatic castration-resistant prostate cancer patients with non-BRCA1/2 HRR gene mutations.
AstraZeneca's EGFR-inhibitor has now demonstrated an 'overwhelming' disease-free survival and CNS recurrence benefit, but overall survival benefit remains unknown.
In an analyst briefing, Pfizer described plans to advance several precision oncology assets in earlier disease settings and in combination with other therapies.
The company is developing T-cell receptor therapies, several of which have entered early-phase trials, that target unique peptides identified through mass spectrometry.
Researchers are homing in on the functional state of PD-L1 and PD-1 receptors in patients' tumors, rather than their expression levels, to predict checkpoint inhibitor response.
